https://www.selleckchem.com/pr....oducts/cx-4945-silmi
G-mono-, G-bendamustine and G-FC-treated patients with unmutated immunoglobulin heavy chain trended towards shorter progression-free survival. Achievement of minimal residual disease negativity was greatest in 1L patients treated with G-FC. In this final analysis of the GREEN trial, the safety profile of G was consistent with current risk management strategies. Biomarker analyses supported efficacy in the specific subgroups.A simple and isocratic reverse-phase liquid chromatography with mass spectrometric method has been d
Like
Comment
Share
